Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a potential acquisition target for larger biopharma firms looking to enter the obesity market.

Guggenheim rated Metsera a "Buy" with a $56 price target on its ultra-long-acting nutrient-stimulating hormone (NuSH) analog pipeline. The firm sees Metsera’s lead GLP-1 receptor agonist, MET-097i, as a strong contender in the obesity market, with combination potential driving further value. Guggenheim noted that positive data in late 2025 could double the stock’s value over the next 18-24 months.

Bank of America also started with a "Buy" rating and a $38 price objective, emphasizing Metsera’s multi-asset approach in obesity, including both injectable and oral platforms. The firm highlighted five key clinical catalysts expected in 2025 and noted that Metsera’s $640 million cash balance should fund operations through 2026, when Phase 3 trials are anticipated to begin.

Cantor also initiated coverage at "Overweight," pointing to Metsera’s broad obesity pipeline, which it says rivals that of large-cap players. The firm believes Metsera’s lead GLP-1 injectable could demonstrate weight loss efficacy similar to Eli Lilly’s Tirzepatide and sees substantial upside from upcoming clinical readouts in 2025.